Acriptega 90 Tablets (TLD Regimen) Price and Uses in Nigeria
Acriptega is a highly effective, once-daily fixed-dose combination medication used for the treatment of HIV-1 infection. Often referred to as the TLD regimen, it is the preferred first-line therapy recommended by the World Health Organization (WHO) and the Nigerian National HIV Treatment Guidelines due to its high efficacy and low risk of side effects.
This 90-tablet pack is designed for Multi-Month Dispensing (MMD), providing a convenient 3-month supply. This reduces the need for frequent pharmacy or clinic visits and helps patients stay consistent with their treatment plan.
Active Ingredients and Composition
Each film-coated Acriptega tablet contains three powerful antiretroviral agents:
- Dolutegravir (50mg): An integrase inhibitor that stops the virus from replicating.
- Lamivudine (300mg): A nucleoside reverse transcriptase inhibitor (NRTI).
- Tenofovir Disoproxil Fumarate (300mg): A nucleotide reverse transcriptase inhibitor (NtRTI).
Why Choose the TLD Regimen?
The TLD combination is recognized for being "patient-friendly." It has a high genetic barrier to resistance, meaning the virus is less likely to become resistant to the drug compared to older regimens. It is also generally better tolerated, with fewer long-term side effects than Efavirenz-based treatments.
How to Take Acriptega
The standard dosage is one tablet daily, taken at the same time each day. It can be taken with or without food. Consistency is critical for maintaining viral suppression and long-term health. If you have questions about your specific routine, you can speak with a GoMed pharmacist for professional guidance.
Storage and Handling
Acriptega tablets are sensitive to moisture. Always keep the bottle tightly closed and store it in a cool, dry place below 30°C. Do not remove the desiccant (silica gel) from the bottle as it protects the medicine.
Note: While Acriptega is primarily used for HIV treatment (ART), healthcare providers may also prescribe it as part of a Post-Exposure Prophylaxis (PEP) regimen following potential exposure.